Demand for monoclonal antibody treatments in the U.S. is far outpacing the available supply, as drugmakers endeavor to increase production.
Photo:
Emily Elconin/Bloomberg News
Before Omicron, the U.S. relied more heavily on the Regeneron and Lilly products.
Photo:
Shannon Stapleton/Reuters
As Omicron cases rise, makers of monoclonal antibody drugs have worked to diversify production in an effort to increase output.
Photo:
Star Tribune/Zuma Press
Hospitals nationwide have been forced to ration doses of the sotrovimab monoclonal antibody treatment for their most at-risk patients.
Photo:
Hannah Beier/Reuters
More